explore -WSS

explore

author：leisure time 2025-09-05 11:27:25 - browse：5

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： With clinical trial data readouts, here's how to spot spin

knowledge

WSS

Most antidepressants don't work on kids, teens, study finds

How to pay for weight loss drugs and save Medicare

FDA investigates CAR

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Is it ever OK for doctors to lie to their patients?

AI for drug discovery: Experts on separating hype from reality

hotspot

explore

leisure time

Sports medicine is finally prioritizing gender equality

The creative science of coining drug names

Medicare proposal to cover medical devices draws a mixed reaction

ReNAgade cuts staff seven months after raising $300 million

The cancer drug shortage isn’t new — and neither are the solutions

BIO to announce reorganization, senior leaders expected to depart

In Memoriam: Notable people who died in 2023

Crowdfunding for medical bills sidesteps core problem, author says

Jerome Adams on the need for new antivirals for Covid

Brain MRIs reveal impact of 'toxic stress' on Black children

focus

Most antidepressants don't work on kids, teens, study finds

AI for drug discovery: Experts on separating hype from reality

Welsh Carson private equity firm escapes from FTC antitrust case

The effects of a landmark ruling on DNA ownership are becoming clearer

As health system earnings go up, health insurance stocks go down

Despite FDA concern, risk that CAR

entertainment

focus

knowledge

entertainment